BD Joins Forces with the University of Pennsylvania
BD (Becton, Dickinson and Company) (NYSE: BDX), a renowned leader in medical technology, has embarked on an innovative collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania. This partnership aims to push the boundaries of immunotherapy by employing advanced flow cytometry techniques to delve deeper into the complexities of the human immune system.
Leveraging Cutting-Edge Flow Cytometry Technology
The collaboration’s highlight is the development of a groundbreaking high-parameter flow cytometry panel that will enhance our understanding of various cellular characteristics, including critical phosphorylation markers. This detailed profiling offers valuable insights into how individual cells react to diseases and the medications intended to combat them. With this technology, researchers are gearing up for an ambitious immune profiling study that aims to involve around 1,000 patients.
Transforming Immune Research
This study, set to commence soon, is a part of a larger initiative with the Penn Colton Center for Autoimmunity that strives to transform how researchers approach immune profiling. The BD FACSDiscover™ A8 Cell Analyzer plays a pivotal role in this project, combining its advanced spectral and real-time imaging capabilities with the BD Rhapsody™ System, along with a suite of both reagents and software designed to maximize research outcomes.
Collaboration: A Pathway to Innovation
Dr. E. John Wherry, the esteemed director of I3H, emphasized the importance of collaboration between the academic and industrial realms in this initiative. He highlighted how the partnership pools cross-functional expertise to develop precise medical treatments, which could significantly expedite advancements in therapeutic approaches based on deeper insights gleaned from the human immune system.
Commitment to Advancing Healthcare
This collaboration embodies a shared vision to harness the potential of the human immune system for scientific advancement and health improvement. Both organizations are committed to enriching the research community through innovative solutions and shared knowledge.
Steve Conly, the worldwide president of BD Biosciences, echoed this sentiment, noting the remarkable shift in high-parameter single-cell studies that are now central to understanding the human immune system. The array of BD’s industry-leading flow cytometry products, along with its analytical tools and informatics solutions, provide crucial support for organizations like I3H in their quest for actionable immunological information.
About BD
BD proudly stands as one of the largest medical technology companies globally, continually pushing the envelope in healthcare. It is dedicated to refining medical discovery, diagnostics, and care delivery through innovative solutions. With a workforce of over 70,000 professionals, BD is passionate about empowering healthcare providers through advanced technology and commitment to better patient outcomes. The company is active in nearly every country, partnering with various organizations to tackle significant global health challenges. Through collaborative efforts, BD aims to enhance healthcare delivery, improve accessibility, and ensure the safety of clinical practices.
Frequently Asked Questions
What is the main goal of the collaboration between BD and the University of Pennsylvania?
The collaboration aims to improve immunotherapy research by utilizing advanced flow cytometry techniques to enhance immune profiling studies.
What technology is central to the BD and University of Pennsylvania partnership?
The BD FACSDiscover™ A8 Cell Analyzer is a central element, enabling detailed analysis of cellular characteristics in immune studies.
How many patients will be involved in the immune profiling study?
Around 1,000 patients are expected to participate in the planned immune profiling study.
Who is Dr. E. John Wherry, and what is his role?
Dr. E. John Wherry is the director of the I3H, and he leads the collaboration, emphasizing its importance in transforming immune profiling.
What is BD’s commitment to global health?
BD is committed to enhancing healthcare through innovative solutions, collaborative research, and a focus on improving patient outcomes across the globe.
